Presentation is loading. Please wait.

Presentation is loading. Please wait.

Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.

Published byTaisto Koskinen Modified over 5 years ago

Similar presentations

Presentation on theme: "Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi."— Presentation transcript:

1 Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin 
Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi Soh, MD, PhD, Katsuyuki Hotta, MD, PhD, Kuniaki Katsui, MD, PhD, Kazuhiko Shien, MD, PhD, Hiromasa Yamamoto, MD, PhD, Takahiro Oto, MD, PhD, Susumu Kanazawa, MD, PhD, Katsuyuki Kiura, MD, PhD, Shinichiro Miyoshi, MD, PhD  The Annals of Thoracic Surgery  Volume 104, Issue 3, Pages (September 2017) DOI: /j.athoracsur Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Positive-pathologic findings of the frozen sections were classified into three categories: (A) epithelium, (B) stromal, and (C) adventitia. Each black circle indicates the invasion of cancer cells. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Kaplan-Meier curves show the overall survival (OS) and recurrence-free survival (RFS) rates for the entire population. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Kaplan-Meier curves show the (A) overall survival (OS) and (B) recurrence-free survival (RFS) rates for patients in the primary surgical procedure (PS) and induction chemoradiotherapy (IC) groups. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi."

Similar presentations

Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.

Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.
Elizabeth A. David, MD, David T

Elizabeth A. David, MD, David T
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer  Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer  Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.
MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy  Michael Augustine Ko, MD, PhD, Guan Zehong, MS, Carl.

MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy  Michael Augustine Ko, MD, PhD, Guan Zehong, MS, Carl.
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Chun Chieh Lin, PhD, MBA, Matthew P

Chun Chieh Lin, PhD, MBA, Matthew P
Outcomes of Reintervention on the Autograft After Ross Procedure

Outcomes of Reintervention on the Autograft After Ross Procedure
Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E

Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Risk of Spinal Cord Injury After Operations of Recurrent Aneurysms of the Descending Aorta  Jorge Flores, MD, Norihiko Shiiya, MD, PhD, Takashi Kunihara,

Risk of Spinal Cord Injury After Operations of Recurrent Aneurysms of the Descending Aorta  Jorge Flores, MD, Norihiko Shiiya, MD, PhD, Takashi Kunihara,
Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy  Colin Schieman, MD, Dennis A. Wigle, MD, PhD,

Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy  Colin Schieman, MD, Dennis A. Wigle, MD, PhD,

Similar presentations

Ads by Google